NEW France Pharma Report Out Now!
France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition.…
Address: 143/147 Bd Anatole France, Saint Denis 93285,France
Tel: +33 (0)1 55 87 30 00
The French Agency for the Safety of Health Products (AFSSAPS) was created by the Act of 1 July 1998 establishing a watchdog and security and safety. This is a public institution under the State supervision of the Ministry of Health. Afssaps’s mission is to ensure job security, quality and proper use of these health products.
Its jurisdiction applies to medicines and raw materials, medical devices and medical devices in vitro diagnostic (or laboratory reagents), for therapeutic products and biological products of human origin (labile blood products, organs, tissues, cells, products of gene and cell therapies), cosmetics and tattoo products.
AFSSAPS is an integeral piece of the public health system. Its activity assessment, monitoring and inspection is based on a high-level expertise to make available health products as safe as possible. It extends into the development and dissemination of information tailored to the needs of health professionals and the public. Moreover, AFSSAPS ensures that each patient receives treated products including pharmaceutical quality, the safety profile and efficacy are demonstrated and validated.
* Public Institution of the State created March 9, 1999, under supervision of the Minister for Health
* A team of nearly a thousand professionals
* More than 2,000 experts meeting in committees and working groups
* Laboratories in Saint-Denis, Lyon and Montpellier
* An operating budget of 109.6 million € for 2009
Pharmacopée
Actualité
Qu’est-ce que la Pharmacopée ?
La Pharmacopée française – 11e édition
Monographies en enquête publique
Réglementation
France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition.…
Jean-Marc Grognet, general manager of Genopole, France’s leading biotechnology cluster, explains the organization’s unique triangular structure with the corner points of the cluster being higher education, research, and industry. Grognet…
Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to…
Patrick Mahieux, general manager of ABL Europe, a CDMO specialized in the provision of viral vectors, discusses the company’s history within the Institut Mérieux and, the unique and flexible strategy…
Jaques Chevallet, CEO of Arkopharma, a European leader in herbal medicines and dietary supplements, discusses the company’s development over recent years while sharing his assessment on the current condition of…
Elizabeth Ducottet, the 5th generation CEO of French family company Thuasne, shares the group’s history and goes on to explain how it has evolved into a professionally and innovatively driven…
Marc Oczachowski, CEO of EDAP TMS, a French medtech and global leader in therapeutic ultrasound, elaborates on the history of the company while discussing their newest innovation for the noninvasive…
In an exclusive interview, Dominique Le Guludec, president of the French National Authority for Health (Haute Autorité de Santé (HAS)), offers her insider comments on the changes in French healthcare…
David Lescuyer, managing director of Skyepharma, a specialized CDMO, reflects on the past three years of the company as it transitioned from a drug delivery platform to a fully-fledged service…
Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses the shifting environment of healthcare in…
Françoise Alliot-Launois, VP of the French League Against Rheumatism (AFLAR), discusses the issues around bone and joint infections in France, AFLAR’s work to help patients suffering from these diseases, and…
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
See our Cookie Privacy Policy Here
